Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 22 03:28PM ET
10.83
Dollar change
+0.68
Percentage change
6.70
%
Index- P/E- EPS (ttm)- Insider Own18.87% Shs Outstand28.23M Perf Week2.27%
Market Cap354.36M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float26.55M Perf Month-10.50%
Income- PEG- EPS next Q- Inst Own- Short Float0.01% Perf Quarter-
Sales- P/S- EPS this Y- Inst Trans- Short Ratio0.01 Perf Half Y-
Book/sh0.04 P/B244.03 EPS next Y- ROA- Short Interest0.00M Perf Year-
Cash/sh0.28 P/C38.69 EPS next 5Y- ROE- 52W Range6.53 - 55.00 Perf YTD-62.78%
Dividend Est.- P/FCF- EPS past 5Y- ROI- 52W High-80.31% Beta-
Dividend TTM- Quick Ratio1.00 Sales past 5Y0.00% Gross Margin- 52W Low65.85% ATR (14)1.50
Dividend Ex-Date- Current Ratio1.00 EPS Y/Y TTM- Oper. Margin- RSI (14)45.71 Volatility14.95% 10.01%
Employees10 Debt/Eq1.40 Sales Y/Y TTM- Profit Margin- Recom- Target Price-
Option/ShortNo / Yes LT Debt/Eq1.11 EPS Q/Q- Payout- Rel Volume0.26 Prev Close10.15
Sales Surprise- EPS Surprise- Sales Q/Q- Earnings- Avg Volume102.69K Price10.83
SMA20-2.04% SMA50-3.55% SMA200-7.61% Trades Volume24,768 Change6.70%
Apr-11-24 09:31AM
Apr-04-24 09:31AM
Mar-28-24 09:31AM
Mar-19-24 09:31AM
Mar-13-24 09:31AM
09:31AM Loading…
Mar-06-24 09:31AM
Feb-29-24 05:44PM
Feb-20-24 09:31AM
Feb-13-24 09:31AM
Feb-08-24 09:31AM
Feb-06-24 09:31AM
Jan-31-24 10:00AM
FibroBiologics, Inc. engages in the development and commercialization of cell therapies. It focuses on treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. The firm's product pipeline includes CybroCell, CYMS101, CYWC628, TCB190, and CYTER915. The company was founded by Peter O'Heeron on April 8, 2021 and is headquartered in Houston, TX.